Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Enliven Therapeutics, Inc. (ELVN) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Enliven Therapeutics, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1672619.
Total stock buying since 2020: $105,368,741.
Total stock sales since 2020: $97,141,123.
Total stock option exercises since 2020: $2,198,969.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 256,519 | $5,339,567 | 64,700 | $150,625 |
| 2024 | 0 | $0 | 2,782,453 | $62,544,973 | 433,420 | $1,891,769 |
| 2023 | 32,380 | $177,203 | 4,552,864 | $26,732,320 | 103,867 | $134,676 |
| 2022 | 1,568,996 | $3,591,548 | 1,017,890 | $1,519,495 | 0 | $0 |
| 2021 | 4,666,665 | $27,999,990 | 358,579 | $848,518 | 0 | $0 |
| 2020 | 4,600,000 | $73,600,000 | 6,250 | $156,250 | 6,250 | $21,899 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-04-11 | Kintz Samuel (PRESIDENT AND CEO) | Option Ex | 47,709 | 1.12 | 53,434 |
| 2024-04-11 | Patel Anish (CHIEF OPERATING OFFICER) | Sale | 17,500 | 25.03 | 438,095 |
| 2024-04-11 | Patel Anish (CHIEF OPERATING OFFICER) | Option Ex | 14,903 | 2.48 | 36,959 |
| 2024-04-11 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Sale | 30,000 | 25.04 | 751,320 |
| 2024-04-11 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Option Ex | 30,000 | 1.12 | 33,600 |
| 2024-04-11 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Sale | 14,000 | 24.46 | 342,398 |
| 2024-04-11 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Option Ex | 14,000 | 2.48 | 34,720 |
| 2024-04-11 | Ballal Rahul D. | Sale | 53,400 | 24.45 | 1,305,469 |
| 2024-04-11 | Ballal Rahul D. | Option Ex | 53,400 | 16.14 | 861,876 |
| 2024-04-11 | Collins Helen Louise (CHIEF MEDICAL OFFICER) | Sale | 20,000 | 25.07 | 501,480 |
| 2024-04-11 | Collins Helen Louise (CHIEF MEDICAL OFFICER) | Option Ex | 20,000 | 2.48 | 49,600 |
| 2024-04-11 | Heyman Richard A. | Sale | 5,694 | 25.02 | 142,435 |
| 2024-04-10 | Ballal Rahul D. | Sale | 13,600 | 21.01 | 285,749 |
| 2024-04-10 | Ballal Rahul D. | Option Ex | 13,600 | 12.60 | 171,360 |
| 2024-04-08 | Patel Anish (CHIEF OPERATING OFFICER) | Sale | 4,875 | 18.95 | 92,381 |
| 2024-04-04 | Ballal Rahul D. | Sale | 3,485 | 19.15 | 66,730 |
| 2024-04-04 | Ballal Rahul D. | Option Ex | 3,485 | 12.60 | 43,911 |
| 2024-04-01 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Sale | 12,000 | 18.63 | 223,548 |
| 2024-04-01 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2024-04-01 | Ballal Rahul D. | Sale | 3,237 | 19.08 | 61,758 |
| 2024-04-01 | Ballal Rahul D. | Option Ex | 3,237 | 9.06 | 29,327 |
| 2024-03-27 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Sale | 3,250 | 18.47 | 60,024 |
| 2024-03-27 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Option Ex | 3,250 | 2.48 | 8,060 |
| 2024-03-25 | Kintz Samuel (PRESIDENT AND CEO) | Sale | 12,000 | 17.66 | 211,980 |
| 2024-03-25 | Kintz Samuel (PRESIDENT AND CEO) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2024-03-20 | Ballal Rahul D. | Sale | 13,278 | 19.16 | 254,459 |
| 2024-03-20 | Ballal Rahul D. | Option Ex | 13,278 | 5.52 | 73,294 |
| 2024-03-19 | Heyman Richard A. | Sale | 1,270 | 14.50 | 18,418 |
| 2024-03-06 | Patel Anish (CHIEF OPERATING OFFICER) | Sale | 4,875 | 15.64 | 76,240 |
| 2024-02-29 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Sale | 12,000 | 16.70 | 200,352 |
| 2024-02-29 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2024-02-27 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Sale | 3,250 | 16.97 | 55,162 |
| 2024-02-27 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Option Ex | 3,250 | 2.48 | 8,060 |
| 2024-02-15 | Heyman Richard A. | Sale | 1,270 | 17.41 | 22,117 |
| 2024-02-06 | Patel Anish (CHIEF OPERATING OFFICER) | Sale | 4,875 | 15.11 | 73,656 |
| 2024-01-30 | Heyman Richard A. | Sale | 1,270 | 16.41 | 20,839 |
| 2024-01-29 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Sale | 12,000 | 15.86 | 190,260 |
| 2024-01-29 | Lyssikatos Joseph P (CHIEF SCIENTIFIC OFFICER) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2024-01-29 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Sale | 3,250 | 15.81 | 51,389 |
| 2024-01-29 | Hohl Benjamin (CHIEF FINANCIAL OFFICER) | Option Ex | 3,250 | 2.48 | 8,060 |
| 2024-01-25 | Kintz Samuel (President and CEO) | Sale | 12,000 | 15.41 | 184,944 |
| 2024-01-25 | Kintz Samuel (President and CEO) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2024-01-22 | Patel Anish (Chief Operating Officer) | Sale | 4,875 | 15.13 | 73,783 |
| 2024-01-02 | Patel Anish (Chief Operating Officer) | Sale | 11,000 | 15.01 | 165,055 |
| 2024-01-02 | Hohl Benjamin (Chief Financial Officer) | Sale | 9,383 | 15.01 | 140,838 |
| 2024-01-02 | Hohl Benjamin (Chief Financial Officer) | Option Ex | 9,383 | 2.48 | 23,269 |
| 2023-12-29 | Patel Anish (Chief Operating Officer) | Sale | 20 | 15.00 | 300 |
| 2023-12-29 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 12,000 | 14.45 | 173,448 |
| 2023-12-29 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2023-12-29 | Hohl Benjamin (Chief Financial Officer) | Sale | 20 | 15.00 | 300 |
| 2023-12-29 | Hohl Benjamin (Chief Financial Officer) | Option Ex | 20 | 2.48 | 49 |
| 2023-12-28 | Patel Anish (Chief Operating Officer) | Sale | 2,520 | 15.08 | 37,996 |
| 2023-12-28 | Hohl Benjamin (Chief Financial Officer) | Sale | 2,467 | 15.07 | 37,187 |
| 2023-12-28 | Hohl Benjamin (Chief Financial Officer) | Option Ex | 2,467 | 2.48 | 6,118 |
| 2023-12-26 | Kintz Samuel (President and CEO) | Sale | 12,000 | 14.64 | 175,704 |
| 2023-12-26 | Kintz Samuel (President and CEO) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2023-12-26 | Patel Anish (Chief Operating Officer) | Sale | 102 | 15.01 | 1,530 |
| 2023-12-26 | Hohl Benjamin (Chief Financial Officer) | Sale | 100 | 15.00 | 1,500 |
| 2023-12-26 | Hohl Benjamin (Chief Financial Officer) | Option Ex | 100 | 2.48 | 248 |
| 2023-12-22 | Kintz Samuel (President and CEO) | Sale | 8,175 | 13.05 | 106,659 |
| 2023-12-22 | Kintz Samuel (President and CEO) | Option Ex | 8,175 | 1.12 | 9,156 |
| 2023-12-22 | Patel Anish (Chief Operating Officer) | Sale | 983 | 15.03 | 14,775 |
| 2023-12-22 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 6,546 | 13.07 | 85,530 |
| 2023-12-22 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 6,546 | 1.12 | 7,331 |
| 2023-12-22 | Hohl Benjamin (Chief Financial Officer) | Sale | 1,030 | 15.07 | 15,525 |
| 2023-12-22 | Hohl Benjamin (Chief Financial Officer) | Option Ex | 1,030 | 2.48 | 2,554 |
| 2023-12-22 | Heyman Richard A. (Director) | Sale | 203 | 13.00 | 2,639 |
| 2023-12-21 | Kintz Samuel (President and CEO) | Sale | 20 | 13.00 | 260 |
| 2023-12-21 | Kintz Samuel (President and CEO) | Option Ex | 20 | 1.12 | 22 |
| 2023-12-21 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 20 | 13.00 | 260 |
| 2023-12-21 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 20 | 1.12 | 22 |
| 2023-12-21 | Heyman Richard A. (Director) | Sale | 13 | 13.00 | 169 |
| 2023-12-20 | Kintz Samuel (President and CEO) | Sale | 7,779 | 13.01 | 101,235 |
| 2023-12-20 | Kintz Samuel (President and CEO) | Option Ex | 7,779 | 1.12 | 8,712 |
| 2023-12-20 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 8,688 | 13.01 | 113,048 |
| 2023-12-20 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 8,688 | 1.12 | 9,730 |
| 2023-12-20 | Heyman Richard A. (Director) | Sale | 4,025 | 13.02 | 52,413 |
| 2023-12-19 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 200 | 13.00 | 2,600 |
| 2023-12-19 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 200 | 1.12 | 224 |
| 2023-12-19 | Heyman Richard A. (Director) | Sale | 255 | 13.00 | 3,315 |
| 2023-11-03 | Kintz Samuel (President and CEO) | Sale | 8,026 | 13.08 | 104,996 |
| 2023-11-03 | Kintz Samuel (President and CEO) | Option Ex | 8,026 | 1.12 | 8,989 |
| 2023-11-03 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 8,546 | 13.08 | 111,747 |
| 2023-11-03 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 8,546 | 1.12 | 9,571 |
| 2023-09-29 | Lyssikatos Joseph P (Chief Scientific Officer) | Sale | 12,000 | 13.62 | 163,500 |
| 2023-09-29 | Lyssikatos Joseph P (Chief Scientific Officer) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2023-09-26 | Schwab Andrew J. (10% Owner) | Sale | 197,500 | 15.00 | 2,962,500 |
| 2023-09-25 | Kintz Samuel (President and CEO) | Sale | 12,000 | 13.81 | 165,696 |
| 2023-09-25 | Kintz Samuel (President and CEO) | Option Ex | 12,000 | 1.12 | 13,440 |
| 2023-08-24 | Schwab Andrew J. (10% Owner) | Sale | 440,000 | 16.00 | 7,040,000 |
| 2023-05-17 | Orbimed Genesis Gp Llc | Option Ex | 2,125 | 4.28 | 9,095 |
| 2023-05-17 | Gupta Rishi | Option Ex | 2,125 | 4.28 | 9,095 |
| 2023-02-23 | Commodore Capital Lp | Buy | 621 | 22.07 | 13,706 |
| 2023-02-22 | Commodore Capital Lp | Buy | 23,565 | 5.11 | 120,487 |
| 2023-02-22 | Ballal Rahul D. (Chief Executive Officer) | Sale | 32,861 | 4.66 | 153,132 |
| 2023-02-22 | Gray Michael (CFO & COO) | Sale | 9,856 | 4.67 | 46,027 |
| 2023-02-21 | Commodore Capital Lp | Buy | 8,194 | 5.25 | 43,010 |
| 2023-01-30 | Ballal Rahul D. (Chief Executive Officer) | Sale | 11,313 | 3.91 | 44,233 |
| 2023-01-30 | Gray Michael (CFO & COO) | Sale | 3,596 | 3.92 | 14,096 |
| 2023-01-04 | Leonard Braden Michael | Sale | 2,500,000 | 4.00 | 10,000,000 |
| 2022-12-30 | Leonard Braden Michael | Sale | 20,000 | 4.04 | 80,800 |
| 2022-12-29 | Leonard Braden Michael | Sale | 19,843 | 4.04 | 80,165 |
| 2022-12-28 | Leonard Braden Michael | Sale | 157 | 4.04 | 634 |
| 2022-12-23 | Leonard Braden Michael | Sale | 48,922 | 4.06 | 198,623 |
| 2022-12-22 | Leonard Braden Michael | Sale | 1,078 | 4.06 | 4,376 |
| 2022-12-09 | Shah Rajeev M. | Buy | 19,299 | 3.93 | 75,845 |
| 2022-12-08 | Shah Rajeev M. | Buy | 10,600 | 3.75 | 39,750 |
| 2022-10-24 | Shah Rajeev M. | Buy | 26,460 | 3.91 | 103,458 |
| 2022-10-21 | Shah Rajeev M. | Buy | 48,100 | 3.92 | 188,552 |
| 2022-10-20 | Shah Rajeev M. | Buy | 11,342 | 3.95 | 44,800 |
| 2022-10-19 | Shah Rajeev M. | Buy | 125,726 | 3.89 | 488,696 |
| 2022-10-18 | Shah Rajeev M. | Buy | 234,799 | 3.76 | 882,844 |
| 2022-10-17 | Shah Rajeev M. | Buy | 145,672 | 3.36 | 489,457 |
| 2022-06-16 | Leonard Braden Michael | Buy | 83,199 | 1.11 | 92,267 |
| 2022-06-06 | Leonard Braden Michael | Buy | 2,630 | 1.16 | 3,050 |
| 2022-06-03 | Leonard Braden Michael | Buy | 30,800 | 1.14 | 34,988 |
| 2022-05-17 | Leonard Braden Michael | Buy | 26,145 | 1.26 | 32,838 |
| 2022-05-16 | Leonard Braden Michael | Buy | 15,000 | 1.17 | 17,580 |
| 2022-04-22 | Leonard Braden Michael | Buy | 8,000 | 1.38 | 11,040 |
| 2022-04-21 | Leonard Braden Michael | Buy | 552,000 | 1.40 | 772,800 |
| 2022-04-06 | Nea Partners 14, L.p. (10% Owner) | Sale | 255,463 | 1.10 | 281,775 |
| 2022-04-05 | Nea Partners 14, L.p. (10% Owner) | Sale | 439,088 | 1.07 | 469,385 |
| 2022-02-23 | Mott David M (Director) | Buy | 35,257 | 1.46 | 51,475 |
| 2022-02-22 | Mott David M (Director) | Buy | 65,817 | 1.56 | 102,674 |
| 2022-02-18 | Mott David M (Director) | Buy | 50,398 | 1.30 | 65,517 |
| 2022-02-17 | Mott David M (Director) | Buy | 14,595 | 1.17 | 17,076 |
| 2022-02-16 | Mott David M (Director) | Buy | 11,779 | 1.20 | 14,134 |
| 2022-02-15 | Mott David M (Director) | Buy | 19,552 | 1.20 | 23,462 |
| 2022-02-14 | Mott David M (Director) | Buy | 8,500 | 1.18 | 10,030 |
| 2022-02-11 | Mott David M (Director) | Buy | 14,573 | 1.23 | 17,924 |
| 2022-02-10 | Mott David M (Director) | Buy | 8,753 | 1.29 | 11,291 |
| 2022-01-25 | Sonsini Peter W. (10% Owner) | Sale | 102,952 | 1.48 | 151,854 |
| 2022-01-24 | Sonsini Peter W. (10% Owner) | Sale | 19,984 | 1.55 | 31,015 |
| 2022-01-21 | Sonsini Peter W. (10% Owner) | Sale | 11,622 | 1.67 | 19,385 |
| 2022-01-20 | Sonsini Peter W. (10% Owner) | Sale | 6,295 | 1.81 | 11,387 |
| 2022-01-19 | Sonsini Peter W. (10% Owner) | Sale | 13,412 | 1.82 | 24,409 |
| 2022-01-18 | Sonsini Peter W. (10% Owner) | Sale | 6,848 | 1.89 | 12,929 |
| 2022-01-14 | Sonsini Peter W. (10% Owner) | Sale | 9,707 | 1.91 | 18,579 |
| 2022-01-13 | Sonsini Peter W. (10% Owner) | Sale | 7,209 | 1.93 | 13,884 |
| 2022-01-12 | Sonsini Peter W. (10% Owner) | Sale | 4,634 | 2.02 | 9,356 |
| 2022-01-11 | Sonsini Peter W. (10% Owner) | Sale | 2,409 | 2.04 | 4,919 |
| 2022-01-10 | Sonsini Peter W. (10% Owner) | Sale | 1,751 | 2.00 | 3,502 |
| 2022-01-07 | Sonsini Peter W. (10% Owner) | Sale | 14,600 | 2.08 | 30,324 |
| 2022-01-06 | Florence Anthony A. Jr. (10% Owner) | Sale | 10,257 | 2.17 | 22,206 |
| 2022-01-05 | Florence Anthony A. Jr. (10% Owner) | Sale | 8,200 | 2.25 | 18,441 |
| 2022-01-04 | Florence Anthony A. Jr. (10% Owner) | Sale | 13,459 | 2.34 | 31,547 |
| 2021-12-29 | Sonsini Peter W. (10% Owner) | Sale | 15,196 | 2.30 | 34,950 |
| 2021-12-28 | Sonsini Peter W. (10% Owner) | Sale | 24,580 | 2.34 | 57,541 |
| 2021-12-27 | Sonsini Peter W. (10% Owner) | Sale | 27,651 | 2.42 | 66,998 |
| 2021-12-23 | Nea 14 Gp, Ltd (10% Owner) | Sale | 23,961 | 2.41 | 57,746 |
| 2021-12-22 | Nea 14 Gp, Ltd (10% Owner) | Sale | 20,109 | 2.32 | 46,672 |
| 2021-12-21 | Nea 14 Gp, Ltd (10% Owner) | Sale | 41,222 | 2.32 | 95,799 |
| 2021-12-20 | Nea 14 Gp, Ltd (10% Owner) | Sale | 85,123 | 2.27 | 193,144 |
| 2021-12-16 | Nea 14 Gp, Ltd (10% Owner) | Sale | 44,993 | 2.23 | 100,559 |
| 2021-12-15 | Nea 14 Gp, Ltd (10% Owner) | Sale | 28,817 | 2.28 | 65,673 |
| 2021-12-14 | Nea 14 Gp, Ltd (10% Owner) | Sale | 15,093 | 2.56 | 38,638 |
| 2021-12-13 | Nea 14 Gp, Ltd (10% Owner) | Sale | 17,501 | 2.83 | 49,562 |
| 2021-12-10 | Nea 14 Gp, Ltd (10% Owner) | Sale | 8,667 | 2.83 | 24,544 |
| 2021-12-09 | Nea 14 Gp, Ltd (10% Owner) | Sale | 5,666 | 2.95 | 16,692 |
| 2021-07-16 | Chin Mark (Director) | Buy | 1,333,333 | 6.00 | 7,999,998 |
| 2021-07-16 | Bonita David P | Buy | 1,666,666 | 6.00 | 9,999,996 |
| 2021-07-16 | Orbimed Capital Llc | Buy | 1,666,666 | 6.00 | 9,999,996 |
| 2020-12-17 | Ballal Rahul D. (Chief Executive Officer) | Sale | 4,999 | 25.00 | 124,975 |
| 2020-12-17 | Ballal Rahul D. (Chief Executive Officer) | Option Ex | 4,999 | 3.15 | 15,746 |
| 2020-12-14 | Ballal Rahul D. (Chief Executive Officer) | Sale | 1 | 25.00 | 25 |
| 2020-12-14 | Ballal Rahul D. (Chief Executive Officer) | Option Ex | 1 | 3.15 | 3 |
| 2020-12-11 | Gray Michael (CFO & COO) | Sale | 1,250 | 25.00 | 31,250 |
| 2020-12-11 | Gray Michael (CFO & COO) | Option Ex | 1,250 | 4.92 | 6,150 |
| 2020-03-16 | Pfizer Ventures (us) Llc (10% Owner) | Buy | 312,500 | 16.00 | 5,000,000 |
| 2020-03-16 | Arix Bioscience Holdings Ltd (10% Owner) | Buy | 187,500 | 16.00 | 3,000,000 |
| 2020-03-16 | Rock Springs Capital Llc (10% Owner) | Buy | 250,000 | 16.00 | 4,000,000 |
| 2020-03-16 | Chin Mark (Director) | Buy | 187,500 | 16.00 | 3,000,000 |
| 2020-03-16 | Agger Mette Kirstine (Director) | Buy | 187,500 | 16.00 | 3,000,000 |
| 2020-03-16 | Shah Rajeev M. | Buy | 625,000 | 16.00 | 10,000,000 |
| 2020-03-16 | Dalton Barbara (Director) | Buy | 312,500 | 16.00 | 5,000,000 |
| 2020-03-16 | Lundbeckfond Invest A/s (10% Owner) | Buy | 187,500 | 16.00 | 3,000,000 |
| 2020-03-16 | Sandell Scott D (10% Owner) | Buy | 475,000 | 16.00 | 7,600,000 |
| 2020-03-12 | Orbimed Capital Gp Vii Llc (Director) | Buy | 937,500 | 16.00 | 15,000,000 |
| 2020-03-12 | Bonita David P (Director) | Buy | 937,500 | 16.00 | 15,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ELVN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Enliven Therapeutics, Inc. (symbol ELVN, CIK number 1672619) see the Securities and Exchange Commission (SEC) website.